U.S. Markets closed
  • S&P 500

    3,629.65
    -5.76 (-0.16%)
     
  • Dow 30

    29,872.47
    -173.77 (-0.58%)
     
  • Nasdaq

    12,094.40
    +57.62 (+0.48%)
     
  • Russell 2000

    1,845.02
    -8.51 (-0.46%)
     
  • Crude Oil

    45.84
    +0.13 (+0.28%)
     
  • Gold

    1,806.40
    +0.90 (+0.05%)
     
  • Silver

    23.41
    +0.04 (+0.18%)
     
  • EUR/USD

    1.1920
    +0.0024 (+0.2026%)
     
  • 10-Yr Bond

    0.8780
    -0.0040 (-0.45%)
     
  • Vix

    21.25
    -0.39 (-1.80%)
     
  • GBP/USD

    1.3385
    +0.0026 (+0.1954%)
     
  • USD/JPY

    104.3990
    -0.0810 (-0.0775%)
     
  • BTC-USD

    18,697.36
    -343.48 (-1.80%)
     
  • CMC Crypto 200

    368.46
    -2.05 (-0.55%)
     
  • FTSE 100

    6,391.09
    -41.08 (-0.64%)
     
  • Nikkei 225

    26,296.86
    +131.27 (+0.50%)
     

Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions

Zacks Equity Research
·2 min read

One stock that might be an intriguing choice for investors right now is Epizyme Inc EPZM. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical - Biomedical and Genetics space as it currently has a Zacks Industry Rank of 10 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Epizyme is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

Epizyme Inc Price and Consensus

Epizyme Inc Price and Consensus
Epizyme Inc Price and Consensus

Epizyme Inc price-consensus-chart | Epizyme Inc Quote


In fact, over the past month, current quarter estimates have narrowed from a loss of 86 cents per share to a loss of 56 cents per share, while current year estimates have narrowed from a loss of $2.82 per share to a loss of $2.36 per share. This has helped EPZM to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Epizyme. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

This young company’s gigantic growth was hidden by low-volume trading, then cut short by the coronavirus. But its digital products stand out in a region where the internet economy has tripled since 2015 and looks to triple again by 2025.

Its stock price is already starting to resume its upward arc. The sky’s the limit! And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Epizyme, Inc. (EPZM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research